A Phase 2 interventional study of Neoadjuvant treatment and Adjuvant treatment in Neuroendocrine Carcinoma and Digestive Cancer, sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group. Recruiting at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Carcinoma, Neuroendocrine with a site in France — 7 open to participants now, 8 under way, 1 of them phase 3. Carcinoma, Neuroendocrine · France.
Among the 17 studies in Carcinoma, Neuroendocrine with a site in France, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is one of 10 in phase 2, and was the 8th registered.
172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 65 are open to participants now.
Browse Carcinoma, Neuroendocrine studies →7 of the 17 studies in Carcinoma, Neuroendocrine with a site in France are open now. Recruiting first, the newest first:
Intergroupe Francophone de Cancerologie Thoracique · Sites in France
Ages 18+
UNICANCER · Sites in France
Ages 18+
Daiichi Sankyo · Sites in France, United States, Argentina and 15 more countries
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Turning Point Therapeutics, Inc. · Sites in France, United States, Australia and 16 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 46 Carcinoma, Neuroendocrine studies recruiting now, 29 (63%) set no upper age limit and 10 (22%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 1
First in 2006; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is above the median of 60 across 144 interventional studies indexed under Carcinoma, Neuroendocrine.
Median enrollment 157 across the 16 interventional studies, 90 across the 1 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
GERCOR - Multidisciplinary Oncology Cooperative Group is the lead sponsor of 76 studies on the registry; 12 are open to participants now.
GERCOR - Multidisciplinary Oncology Cooperative Group has 1 study filed under Carcinoma, Neuroendocrine — fewer than ten, so there is no comparison to draw.
2 of the studies in Carcinoma, Neuroendocrine with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04268121GERCOR - Multidisciplinary Oncology Cooperative GroupEfficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | 2027-01 |
| NCT05599984AbbVieStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Carcinoma, Neuroendocrine with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
NEONEC is a single-phase, phase II study evaluating the efficacy of the 12-month neoadjuvant chemotherapy in patients with locally differentiated digestive NEC. The recommended chemotherapy is based on the current reference combination of platinum (cisplatin or carboplatin) and etoposide (VP16). For anorectal locations, radiochemotherapy is proposed to avoid the morbidity of conventional surgery.
The objective of the study is to improve relapse-free survival (RFS) in NEC patients treated with neoadjuvant chemotherapy followed by surgery or chemoradiotherapy.
In parallel, we will perform a prospective cohort study with patients whose diagnosis is made during surgery, who have not received neoadjuvant treatment, and who are offered an adjuvant treatment of the same type (combination of platinum and platinum salts and etoposide).
A total of 48 patients is to be included in phase II and 30 patients in prospective cohort during the inclusion period of phase II.
Phase II study treatment:
Neoadjuvant chemotherapy: Administration of 4 cycles of chemotherapy (3 months) with platinum based chemotherapy (carboplatin or cisplatin, at the choice of the investigator) + etoposide.
Surgery or chemoradiotherapy depending on the tumor localization (the irradiation modalities and associated chemotherapy treatment will be left to the discretion of the referring radiotherapists according to current recommendations for each localization).
Prospective cohort:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase II
5. Age ≥ 18 years, 6. Written obtained from the patient, willing and able to comply with the protocol, 7. Registration in a National Health Care System (Protection Universelle Maladie [PUMa] included), 8. For female patients of , negative pregnancy test within 7 days before starting the study treatment.
Men and women are required to use a reliable and adequate during the study (if applicable) during the period of treatment and during 6 months from the last treatment administration.
Prospective cohort
Men and women are required to use a reliable and adequate birth control methods during the study (if applicable) during the period of treatment and during 6 months from the last treatment administration.
Exclusion Criteria:
Phase II
Prospective cohort
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prospective, open, multi center, one-arm, national phase II study evaluating the benefits in terms of disease-free survival (DFS) at 12 months after the administration of neoadjuvant treatment in patients with localized digestive neuroendocrine carcinomas
Drug: Neoadjuvant treatment
Evaluation of DFS at 12 months in patients who underwent surgery and received adjuvant chemotherapy
Drug: Adjuvant treatment
4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
Also known as: cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin
Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide
Also known as: cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin
Relapse-free survival (RFS) - phase II
Interval between the date of the start of treatment (chemotherapy) and the date of first relapse or death (all causes). Relapse is defined according to RECIST version 1.1 criteria.
Time frame: At 12 months
Relapse-free survival (RFS) - prospective cohort
Interval between the date of the start of treatment (chemotherapy) and the date of first relapse or death (all causes). Relapse is defined according to RECIST version 1.1 criteria.
Time frame: At 12 months
Number of patient in response in pre-operative or prior radiochemotherapy (if applicable) - Phase II
according to RECIST 1.1
Time frame: At 3 months after the beginning of treatment (up to 36 months)
Number of patients who do not benefit from surgery or radiochemotherapy (if applicable) - Phase II
Number of patients who do not benefit from surgery or radiochemotherapy (if applicable) - Phase II
Time frame: Up to 39 months
Number of patients operated after neoadjuvant chemotherapy or receiving radiochemotherapy (if applicable) - Phase II
Number of patients operated after neoadjuvant chemotherapy or receiving
Time frame: Up to 39 months
Overall survival (OS) - Phase II
Overall survival (OS) is defined as the time from study enrollment to death (from any cause) or to the last date the patients was known to be alive.
Time frame: up to 48 months
Overall survival (OS) - Prospective cohort
Overall survival (OS) is defined as the time from study enrollment to death (from any cause) or to the last date the patients was known to be alive.
Time frame: Up to 48 months
Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Phase II
Patients will be assessed for AEs throughout the study at every visit during treatment. Investigators using the NCI-CTCAE version 5.0 will grade the severity of AEs. Institute Common Terminology Criteria for Adverse Toxicity Study (NCI-CTCAE) version 5.0
Time frame: Up to 43 months
Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Prospective cohort
Patients will be assessed for AEs throughout the study at every visit during treatment. Investigators using the NCI-CTCAE version 5.0 will grade the severity of AEs. Institute Common Terminology Criteria for Adverse Toxicity Study (NCI-CTCAE) version 5.0
Time frame: Up to 43 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Jan 2027, 72 months after the start.
Of 43 phase 2 interventional studies under Carcinoma, Neuroendocrine, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 91. This study's planned 72 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GERCOR - Multidisciplinary Oncology Cooperative Group